Dialysis of Drugs

Theguidelinescontainedinthisapplicationaredesignedtoprovideextensive,easy-to-readinformationregardingthedialyzabilityofdrugs.Numerousliteraturesourceshavebeenusedinpreparingtheguidelines.Formanydrugs,includingnewly-approvedmedications,investigationalagentsandmedicationsavailableinothercountries,therehavebeennodialysispharmacokineticstudies.Insomecases,theavailabledatamayconflict.Conditionsofdialysisusedinpublishedstudiesmaynotreflectcurrentdialysispracticeandtechnology.Variationsinthedurationofdialysis,bloodanddialysateflowrates,dialysismembranes,andwhetherperitonealdialysisiscontinuousorintermittent,willallaffectdrugremoval.Theseguidelinesdistinguishbetweenconventionalhemodialysisandhighpermeability(high-flux)hemodialysiswheresuchdataareavailable.Noinformationisprovidedondrugdialyzabilitywithcontinuousrenalreplacementtherapy(CRRT)orwithplasmapheresis.Foradditionalinformationonspecificdrugs,thereadershouldconsulttheprimaryliterature.

Usersofthisapplicationarereferredtowww.renalpharmacyconsultants.comforbackgroundandexplanatorymaterialtoassistintheinterpretationofthetabulardata.Thewebsiteprovidesspecificinformationaboutfactorsthatinfluencedrugdialyzabilityandspecialconsiderations,suchasCRRT,plasmapheresisanddrugsofabuse.Usersmustbefamiliarwiththisinformationpriortousingthecontentofthisapplication.Thewebsitealsoincludesatablepresentingsievingcoefficientdatafrominvitroandinvivoevaluations,whichcanbeusedtopredictdosingrequirementsinCRRT,andatableregardingremovalofdrugsofabuse.